2020 International Conference on Computer Science, Engineering and Applications (ICCSEA) 2020
DOI: 10.1109/iccsea49143.2020.9132919
|View full text |Cite
|
Sign up to set email alerts
|

Design and Simulating of a Compact Antenna for WiMAX and LTE Application

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2021
2021
2022
2022

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 19 publications
0
3
0
Order By: Relevance
“…Table 3. Performance comparison with previous work [26]- [28] Reference no Resonance frequency (GHz) Size (λg) Max Gain (dBi) Bandwidth (MHz) [26] 3.5 0.70 x 0.47 2.2 140 [27] 3.5 0.68 x 0.25 4.38 170 [28] 3.5 0.88 x 0.75 2.0 110 This work 3.5 0.50 x 0.39 5 274…”
Section: Rmpa Design On Metamaterials Substratementioning
confidence: 99%
“…Table 3. Performance comparison with previous work [26]- [28] Reference no Resonance frequency (GHz) Size (λg) Max Gain (dBi) Bandwidth (MHz) [26] 3.5 0.70 x 0.47 2.2 140 [27] 3.5 0.68 x 0.25 4.38 170 [28] 3.5 0.88 x 0.75 2.0 110 This work 3.5 0.50 x 0.39 5 274…”
Section: Rmpa Design On Metamaterials Substratementioning
confidence: 99%
“…AChE is a cholinesterase responsible for catalyzing the hydrolysis of the neurotransmitter acetylcholine (ACh) in the cholinergic synapse . This enzyme is an attractive target for the treatment of many neurodegenerative disorders such as Alzheimer's disease (AD) . Like the AChE, the Butyrylcholinesterase (BChE) enzyme called nonspecific cholinesterase, also belongs to cholinesterases family of enzymes, playing only a supportive role, being it more efficient in the hydrolysis at high ACh concentrations .…”
Section: Introductionmentioning
confidence: 99%
“…The inhibition of these enzymes could, therefore, improve symptoms of this disease. The inhibition of this enzyme has emerged as a promising strategy for the treatment of AD, being the tacrine the first AChE inhibitor approved for the treatment of AD . However, due to its toxicity, other molecules have been developed .…”
Section: Introductionmentioning
confidence: 99%